BACKGROUND: Bevacizumab is a specific inhibitor of angiogenesis and a neutralising antibody against vascular endothelial growth factor (VEGF). The effect of bevacizumab was evaluated on malignant fibrous histiocytoma (MFH) in vivo using an animal model. MATERIALS AND METHODS: MFH cell line, NaraH, was implanted to athymic nude mice which were randomly divided into a treatment and a control group. The change in body weight and tumour volume were evaluated and immunohistochemical analysis was performed of microvessel density (MVD) and VEGF expression in the tumour tissue. RESULTS: Bevacizumab significantly induced inhibition of tumour growth, reducing tumour volume to 48% at the end of experiment. Intratumoural MVD was significantly decreased in the bevacizumab treatment group compared to the control group. A positive correlation was found between tumour volume and MVD. CONCLUSION: Bevacizumab suppressed MFH tumour growth by inhibiting tumoural angiogenesis. The current study suggests that bevacizumab may be a novel therapeutic agent for MFH.
BACKGROUND:Bevacizumab is a specific inhibitor of angiogenesis and a neutralising antibody against vascular endothelial growth factor (VEGF). The effect of bevacizumab was evaluated on malignant fibrous histiocytoma (MFH) in vivo using an animal model. MATERIALS AND METHODS: MFH cell line, NaraH, was implanted to athymic nude mice which were randomly divided into a treatment and a control group. The change in body weight and tumour volume were evaluated and immunohistochemical analysis was performed of microvessel density (MVD) and VEGF expression in the tumour tissue. RESULTS:Bevacizumab significantly induced inhibition of tumour growth, reducing tumour volume to 48% at the end of experiment. Intratumoural MVD was significantly decreased in the bevacizumab treatment group compared to the control group. A positive correlation was found between tumour volume and MVD. CONCLUSION:Bevacizumab suppressed MFH tumour growth by inhibiting tumoural angiogenesis. The current study suggests that bevacizumab may be a novel therapeutic agent for MFH.
Authors: Corinne N Riggin; Stephanie N Weiss; Ashley B Rodriguez; Harina Raja; Mengcun Chen; Susan M Schultz; Chandra M Sehgal; Louis J Soslowsky Journal: Ann Biomed Eng Date: 2022-03-18 Impact factor: 4.219
Authors: Juan Martín Liberal; Laura Lagares-Tena; Miguel Sáinz-Jaspeado; Silvia Mateo-Lozano; Xavier García Del Muro; Oscar M Tirado Journal: Sarcoma Date: 2012-06-03
Authors: Corinne N Riggin; Ashley B Rodriguez; Stephanie N Weiss; Harina A Raja; Mengcun Chen; Susan M Schultz; Chandra M Sehgal; Louis J Soslowsky Journal: J Orthop Res Date: 2020-10-01 Impact factor: 3.102